| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/15/2023 | 586.27% | Truist Securities | $8 → $7 | Maintains | Buy |
| 08/14/2023 | 390.2% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/11/2023 | 880.39% | Wedbush | $16 → $10 | Maintains | Outperform |
| 08/10/2023 | 292.16% | Wells Fargo | $5 → $4 | Maintains | Overweight |
| 08/09/2023 | 782.35% | Barclays | $11 → $9 | Maintains | Overweight |
| 08/09/2023 | 488.24% | RBC Capital | $8 → $6 | Maintains | Outperform |
| 05/10/2023 | 684.31% | Truist Securities | $16 → $8 | Maintains | Buy |
| 05/01/2023 | 390.2% | HC Wainwright & Co. | $15 → $5 | Maintains | Buy |
| 04/28/2023 | 47.06% | B of A Securities | $5 → $1.5 | Downgrades | Neutral → Underperform |
| 03/03/2023 | 1370.59% | HC Wainwright & Co. | $25 → $15 | Maintains | Buy |
| 02/27/2023 | 1468.63% | Wedbush | → $16 | Upgrades | Neutral → Outperform |
| 02/23/2023 | 1174.51% | RBC Capital | $22 → $13 | Maintains | Outperform |
| 01/04/2023 | 1370.59% | Wells Fargo | $20 → $15 | Maintains | Overweight |
| 11/07/2022 | 1860.78% | Wells Fargo | $22 → $20 | Maintains | Overweight |
| 06/13/2022 | 390.2% | Wedbush | → $5 | Assumes | → Neutral |
| 04/05/2022 | 1762.75% | Truist Securities | $23 → $19 | Maintains | Buy |
| 05/04/2021 | 2056.86% | RBC Capital | → $22 | Initiates Coverage On | → Outperform |
| 01/06/2021 | 1468.63% | Stifel | → $16 | Initiates Coverage On | → Hold |
| 12/16/2020 | 2350.98% | HC Wainwright & Co. | → $25 | Assumes | → Buy |
| 09/08/2020 | 1860.78% | B of A Securities | → $20 | Reinstates | → Buy |
| 07/07/2020 | 2056.86% | SunTrust Robinson Humphrey | → $22 | Initiates Coverage On | → Buy |
| 06/22/2020 | 1272.55% | HC Wainwright & Co. | $16 → $14 | Maintains | Buy |
| 11/14/2018 | 978.43% | JP Morgan | $35 → $11 | Maintains | Neutral |
| 11/14/2018 | 978.43% | JP Morgan | $35 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2018 | — | Guggenheim | Downgrades | Buy → Neutral |
What is the target price for Sangamo Therapeutics (SGMO)?
The latest price target for Sangamo Therapeutics (NASDAQ: SGMO) was reported by Truist Securities on August 15, 2023. The analyst firm set a price target for $7.00 expecting SGMO to rise to within 12 months (a possible 586.27% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sangamo Therapeutics (SGMO)?
The latest analyst rating for Sangamo Therapeutics (NASDAQ: SGMO) was provided by Truist Securities, and Sangamo Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Sangamo Therapeutics (SGMO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sangamo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sangamo Therapeutics was filed on August 15, 2023 so you should expect the next rating to be made available sometime around August 15, 2024.
Is the Analyst Rating Sangamo Therapeutics (SGMO) correct?
While ratings are subjective and will change, the latest Sangamo Therapeutics (SGMO) rating was a maintained with a price target of $8.00 to $7.00. The current price Sangamo Therapeutics (SGMO) is trading at is $1.02, which is out of the analyst's predicted range.